Sign inJoin waitlistJoin the waitlist

JR

John Reneau

Physician · Ohio State University College of Medicine

Credentials: · · · · · · · ·

History

Ohio State University College of Medicine
2019–Present

Hematology and Medical Oncology
University of Michigan
2016–2019
Internal Medicine
Mayo Clinic College of Medicine and Science
2013–2016
Texas A&M School of Medicine
2009–2013

Research

TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo
Proceedings of the National Academy of Sciences of the United States of America · 2014 · 160 citations
Preactivation of human MSCs with TNF-α enhances tumor-suppressive activity
Cell stem cell · 2012 · 109 citations
Integrins and proximal signaling mechanisms in cardiovascular disease
Review · Frontiers in bioscience · 2009 · 71 citations

Jonathan Brammer
17 papers
Walter Hanel
14 papers
Robert Baiocchi
13 papers
Ryan Wilcox
12 papers
Beth Christian
11 papers
David Bond
11 papers
Kami Maddocks
11 papers
Narendranath Epperla
11 papers
YS
Yazeed Y Sawalha
11 papers
Lapo Alinari
9 papers
TV
Timothy Voorhees
8 papers · 3 as a fellow
Carlos Murga-Zamalloa
6 papers

Clinical trials

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Principal investigator · Recruiting · Phase 1
John Reneau
2022–2027
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
Principal investigator · Completed · Phase 2
Ohio State University Comprehensive Cancer Center
2020–2024
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
Principal investigator · Completed · Phase 2
John Reneau
2018–2025
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Site PI · Recruiting · Phase 3
Corvus Pharmaceuticals, Inc.
2024–2028